Intelligence / Healthtech / New Clinical Trials / Suisselle
Clinicaltrial registered10 Nov 2026
Suisselle
10 Nov 2026: Trial registered · Effectiveness and Safety of Cellbooster Glow in Healthy Subjects. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 10 Nov 2026
- Title
- Effectiveness and Safety of Cellbooster Glow in Healthy Subjects
- Conditions
- Wrinkle Appearance, Skin Hydration in Healthy Volunteers, Skin Pigmentation, Skin Laxity
- Phase
- Not applicable
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- France
- Country
- France
- Reference
- NCT07929870
- Location
- France
What this signal means
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS
Find the decision makers at Suisselle
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Suisselle in our registers.
More from France
New Clinical Trials
17 NovAstraZenecatrial registered · A Study to Investigate the Efficacy and Safety of Dato-DXd-based Combinations in Participants With TROP2 NMR+ NSCLCClinical17 NovSensoriontrial registered · A Clinical Trial With SENS-601, Injected With SPHYNX Administration System, in the Pediatric Population Presenting With Hearing Loss Related to Pathogenic Variation(s) of GJB2 GeneClinical10 NovBoehringer Ingelheimtrial registered · A Study to Test Obrixtamig Treatment in People With Different Types of Advanced Cancer Who Took Part in a Previous Study With ObrixtamigClinical10 NovEli Lilly and Companytrial registered · A Study of LY4336619 in Adult Participants With Advanced Solid TumorsClinical10 NovSuisselletrial registered · Effectiveness and Safety of Cellbooster Hair in Healthy SubjectsClinical9 NovBoston Scientific Corporationtrial registered · The Evaluation of User Experience With FARAVIEW™ Technology of the OPAL HDx™ Mapping System When Used With the FARAWAVE NAV™ ULTRA Pulsed Field Ablation Catheter in the Treatment of Atrial FibrillationClinical
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.